CLINICO-ECONOMIC ANALYSIS OF EFFECTIVENESS OF CANDESARTAN AND LOSARTAN IN PATIENTS WITH HYPERTENSION IN TYPICAL PRACTICE
The research was about comparing clinico-economic analysis of candesartan and losartan in patients with hypertension in a typical practice. The study was carried out using decision tree model building. The reduction in systolic blood pressure and diastolic blood pressure in patients with hypertension were taken as effectiveness criteria. It has been shown that the cost of treating one patient with hypertension (monotherapy) using Lozap (losartan) was lower than in case of Atacand (candesartan) - 788,55 and 1727,95 rubles respectively to the 8th week of treatment. Effectiveness of Atacand was greater than the effectiveness of Lozap on two criteria («Reducing SBP» and «Reducing DBP»), so the ratio of «cost-effectiveness» was still lower for losartan (Lozap). Thus, the use of Atacand is not costeffective comparing to Lozap. Comparison of candesartan (Atacand) with the original drug losartan (Cozaar) in a sensitivity analysis in patients with hypertension showed clinical and economic advantage of Atacand to Cozaar by «reducing diastolic blood pressure». Sensitivity analysis showed that the administration of the half of 32 mg tablet with the required dosage of 16 mg of Atacand with the minimum price of Atacand was more economically-based because of «reducing diastolic blood pressure».